首页> Clinical infectious diseases : an official publication of the Infectious Diseases Society of America> Antiviral Activity, Safety, and Exposure-Response Relationships of GSK3532795, a Second-Generation Human Immunodeficiency Virus Type 1 Maturation Inhibitor, Administered as Monotherapy or in Combination With Atazanavir With or Without Ritonavir in a Phase 2a Randomized, Dose-Ranging, Controlled Trial (AI468002).

Antiviral Activity, Safety, and Exposure-Response Relationships of GSK3532795, a Second-Generation Human Immunodeficiency Virus Type 1 Maturation Inhibitor, Administered as Monotherapy or in Combination With Atazanavir With or Without Ritonavir in a Phase 2a Randomized, Dose-Ranging, Controlled Trial (AI468002).

导出 OA

翻译打印收藏纠错

第一作者： Carey,Hwang

第一单位： Research and Development, Bristol-Myers Squibb, Princeton, New Jersey.

作者： Carey,Hwang ^[1] ; Dirk,Schürmann ^[2] ; Christian,Sobotha ^[3] ; Marta,Boffito ^[4] ; Heather,Sevinsky ^[1] ; Neelanjana,Ray ^[1] ; Palanikumar,Ravindran ^[1] ; Hong,Xiao ^[1] ; Christian,Keicher ^[3] ; Andreas,Hüser ^[3] ; Mark,Krystal ^[5] ; Ira B,Dicker ^[5] ; Dennis,Grasela ^[1] ; Max,Lataillade ^[5]

作者单位： Research and Development, Bristol-Myers Squibb, Princeton, New Jersey. ^[1] Charité Research Organisation GmbH.;Department of Infectious Diseases and Pulmonary Medicine, Charité-Universitätsmedizin Berlin, Germany. ^[2] Charité Research Organisation GmbH. ^[3] St Stephen's Centre, Chelsea and Westminster Hospital, London, United Kingdom. ^[4] Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut. ^[5]

关键词 GSK3532795 HIV-1 infection dose-ranging maturation inhibitor phase 2a study